Healthcare Industry News: migraine
News Release - May 12, 2009
Occlutech Obtains CE Mark for the new Generation PFO & ASD OccludersJENA, Germany, May 12 -- (Healthcare Sales & Marketing Network) -- Occlutech, the leading European developer of septum occluders, today announced that it has obtained CE mark approval for its new generation ASD and PFO occluders, the Figulla Flex.
The Figulla Flex ASD and PFO occluders encompass a new innovative delivery system, making the use of a threaded hub unnecessary. The implantation of the occluder is facilitated by the ability of the delivery system to allow a 45 degree angle before release.
The Occlutech Figulla Flex will be exhibited and demonstrated at the PCR vascular intervention meeting in Barcelona from May 19th to May 22nd.
Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.